Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial.

ABSTRACT:

Background

The prognosis for advanced hepatocellular carcinoma (HCC) remains clinically unsatisfying. Apatinib has proven to be a very effective treatment for advanced HCC in our previous retrospective study. Our aim in this study was to evaluate the efficacy, safety, and toxicity of apatinib in patients with advanced HCC.

Methods

This single-arm, open-label phase II clinical trial enrolled patients with advanced HCC. These patients received apatinib, 500 mg once daily, until disease progression, unacceptable toxicity, consent withdrawal, or death. One treatment cycle consisted of 4 weeks of apatinib treatment. The response evaluation criteria in solid tumors (RECIST) was used to assess tumor response every 1-2 cycles. The primary endpoint was the objective response rate (OR

SUBMITTER: Hou Z 

PROVIDER: S-EPMC7576000 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature